Clinical Validation of Nerveblox, an Artificial Intelligence Software to Support Ultrasound-Guided Regional Anesthesia Procedures
Launched by SMART ALFA TEKNOLOJI SAN. VE TIC. A.S. · Mar 10, 2025
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
This study aims to validate the performance of AI technology in regional anesthesia through a clinical evaluation conducted on the U.S. population.
Data collection method and Analysis:
A total of 40 healthy subjects were enrolled and scanned by three different expert anesthesiologists. Twelve different peripheral nerve and plane block regions supported by the Nerveblox software were scanned bilaterally. Each participant spent approximately 30 minutes in the ultrasound scanning session, with each ultrasound clip lasting 10 seconds.
Age, gender, weight, and height data were collected and r...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Provision of signed and dated informed consent form
- • Stated willingness to comply with all study procedures and availability for the duration of the study
- • In good general health
- Exclusion Criteria:
- • Pregnancy
- • Inability to lie to flat
- • Any complaint or anatomical deformity on the regions to be scanned
About Smart Alfa Teknoloji San. Ve Tic. A.S.
Smart Alfa Teknoloji San. ve Tic. A.Ş. is an innovative clinical trial sponsor focused on advancing medical research and development through cutting-edge technology solutions. With a commitment to enhancing patient outcomes and streamlining trial processes, the company leverages its expertise in data analytics, digital health, and regulatory compliance to facilitate efficient and effective clinical studies. Smart Alfa is dedicated to fostering partnerships with healthcare professionals and institutions to drive forward-thinking approaches in the biopharmaceutical sector, ensuring the development of safe and effective therapies for a range of medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brooklyn, New York, United States
Patients applied
Trial Officials
Gary Scott Shwartz, M.D.
Principal Investigator
AABP Integrative Pain Care and Wellness Clinic, Brooklyn
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported